Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239156 | 0.91 | VNN1 (0.46) | VNN1MAP2K7KMT2AMEN1CNR1 | |
| SCHEMBL20239251 | 0.91 | VNN1 (0.44) | VNN1MAP2K7KMT2APTPN1CYP1A2 | |
| SCHEMBL20259250 | 0.89 | VNN1 (0.44) | VNN1MAP2K7KMT2AMEN1CNR1 | |
| SCHEMBL20472856 | 0.86 | VNN1 (0.42) | VNN1MAP2K7KMT2AMEN1PTPN1 | |
| SCHEMBL20239276 | 0.85 | LOXL2 (0.48) | KMT2AMEN1PTPN1FPR2SMN1; SMN2 | |
| SCHEMBL20239143 | 0.85 | VNN1 (0.44) | VNN1MAP2K7KMT2A | |
| SCHEMBL20472861 | 0.82 | VNN1 (0.45) | VNN1MAP2K7KMT2A | |
| SCHEMBL18249766 | 0.81 | PLAAT3 (0.44) | VNN1MAP2K7 | |
| SCHEMBL20239250 | 0.81 | DGAT2 (0.57) | VNN1MAP2K7KMT2A | |
| SCHEMBL20239244 | 0.81 | DGAT2 (0.48) | VNN1KMT2AMEN1CYP3A4GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | VNN1 3148/4885MAP2K7 4186/4885KMT2A 1748/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | VNN1 3615/4885MAP2K7 4080/4885KMT2A 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.